Clinical trial
Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose…
NCT00477802 · University of Cincinnati, Other · Terminated
Key facts
| NCT number | NCT00477802 |
|---|---|
| Title | Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease |
| Official title | Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study |
| Lead sponsor | University of Cincinnati, Other |
| Collaborators | Allergan Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Parkinson Disease |
| Intervention type | Biological |
| Interventions | Botulinum Toxin Type A, Placebo |
| Enrollment | 8 |
| Start date | May 1, 2007 |
| Primary completion | Nov 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | May 24, 2007 |
| Last update posted | Feb 16, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: